Healthy volunteers help uncover drug interaction secrets

NCT ID NCT07439250

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed phase 1 study looked at how the antifungal drug fluconazole changes the way the body handles the experimental cancer drug olomorasib. Fifteen healthy volunteers took olomorasib alone and then with fluconazole, and researchers measured drug levels in their blood. The goal was to understand if fluconazole affects how much olomorasib gets into the bloodstream and how quickly it is eliminated.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

olomorasib (LY3537982) and fluconazole

What this could lead to

If successful, this study will help doctors understand how to safely dose olomorasib when taken with fluconazole, potentially improving treatment for future patients.

What could go wrong

This is a very early, small study in healthy people, not patients. It only measures drug levels in the blood, not whether the drug works or is safe long-term.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Fortrea Clinical Research Unit - Daytona Beach

    Daytona Beach, Florida, 32117-5116, United States